Pharmacogenetics of breast cancer therapies

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Hertz, Daniel L ^a   McLeod, Howard L ^a   Hoskins, Janelle M ^a  

^a University of North Carolina   (United States)

Author keywords

Breast cancer; Pharmacogenetics; Pharmacogenomics; Tamoxifen; Trastuzumab

Indexed keywords

AROMATASE INHIBITOR; CYTOCHROME P450 2D6; FC RECEPTOR; FLUOXETINE; IMMUNOGLOBULIN FC FRAGMENT LOW AFFINITY RECEPTOR 3A; PACLITAXEL; PAROXETINE; RITUXIMAB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VENLAFAXINE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 72049122975     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70275-9     Document Type: Article

References (49)

1. IARC. World Cancer Report (2008), World Health Organization, Geneva
2. Fisher B., Redmond C., Brown A., et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 4 (1986) 459-471
3. Mortimer J., Flournoy N., Livingston R.B., and Stephens R.L. Aggressive adriamycin-containing regimen (PM-FAC) in estrogen receptor-negative disseminated breast cancer. Results of a Southwest Oncology Group trial. Cancer 56 10 (1985) 2376-2380
4. Liu S, Chia S, Mehl E. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat. 2009 Feb 10 [Epub ahead of print].
5. Menard S., Fortis S., Castiglioni F., et al. HER2 as a prognostic factor in breast cancer. Oncology 61 Suppl 2 (2001) 67-72
6. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 27 (2004) 2817-2826
7. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 23 (2006) 3726-3734
8. Sparano J.A., and Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26 5 (2008) 721-728
9. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. J Clin Oncol 25 33 (2007) 5287-5312
10. Kimchi-Sarfaty C., Oh J.M., Kim I.-W., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 5811 (2007 January 26) 525-528
11. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 3 (2002) 719-726
12. Sondermann P., Huber R., Oosthuizen V., et al. The 3.2-Ångstrom crystal structure of the human IgG1 Fc fragment-FcgammaRIII complex. Nature 406 6793 (2000) 267
13. Fanger M.W., Shen L., Graziano R.F., et al. Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 10 3 (1989) 92-99
14. Wu J., Edberg J.C., Redecha P.B., et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100 5 (1997) 1059-1070
15. Shields R.L., Namenuk A.K., Hong K., et al. High resolution mapping of the binding site on human IgG1 for Fcgamma RI, Fcgamma RII, Fcgamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fcgamma R. J Biol Chem 276 9 (2001) 6591-6604
16. Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E., and de Haas M. Fcgamma RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fcgamma RIIIa, independently of the Fcgamma RIIIa-48L/R/H Phenotype. Blood 90 3 (1997) 1109-1114
17. Warmerdam P.A., van de Winkel J.G., Vlug A., et al. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 147 4 (1991) 1338-1343
18. Clynes R.A., Towers T.L., Presta L.G., et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 4 (2000) 443-446
19. Gennari R., Menard S., Fagnoni F., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10 17 (2004) 5650-5655
20. Arnould L., Gelly M., Penault-Llorca F., et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 94 2 (2006) 259-267
21. Varchetta S., Gibelli N., Oliviero B., et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67 24 (2007) 11991-11999
22. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene. Blood 99 3 (2002) 754-758
23. Weng W.-K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 21 (2003) 3940-3947
24. Kim D.H., Jung H.D., Kim J.G., et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108 8 (2006) 2720-2725
25. Musolino A., Naldi N., Bortesi B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26 11 (2008) 1789-1796
26. Farag S.S., Flinn I.W., Modali R., Lehman T.A., Young D., and Byrd J.C. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103 4 (2004) 1472-1474
27. Galimberti S., Palumbo G.A., Caracciolo F., et al. The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms. J Chemother 19 3 (2007) 315-321
28. Zhang W., Gordon M., Schultheis A.M., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25 24 (2007) 3712-3718
29. Ternant D., Ohresser M., Thomas C., Cartron G., Watier H., and Paintaud G. Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies. Blood 106 4 (2005) 1503-1505
30. Lejeune J., Thibault G., Ternant D., Cartron G., Watier H., and Ohresser M. Evidence for linkage disequilibrium between Fc{gamma}RIIIa-V158F and Fc{gamma}RIIa-H131R polymorphisms in white patients, and for an Fc{gamma}RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 26 33 (2008) 5489-5491
31. Lewis J.S., and Jordan V.C. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591 1-2 (2005) 247-263
32. National Comprehensive Cancer Network. Clinical practice guidelines in oncology - version 2.2007 (2007), National Comprehensive Cancer Network, Inc
33. Desta Z., Ward B.A., Soukhova N.V., and Flockhart D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310 3 (2004) 1062-1075
34. Stearns V., Johnson M.D., Rae J.M., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95 23 (2003) 1758-1764
35. Johnson M.D., Zuo H., Lee K.H., et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85 2 (2004) 151-159
36. Lim Y.C., Desta Z., Flockhart D.A., and Skaar T.C. Endoxifen (4-hydroxy-N-desmethyltamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55 5 (2005) 471-478
37. Lim Y.C., Li L., Desta Z., et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318 2 (2006) 503-512
38. Borges S., Desta Z., Li L., et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80 1 (2006) 61-74
39. Eichelbaum M., Baur M.P., Dengler H.J., Osikowska-Evers B.O., Tieves G., Zekorn C., et al. Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 23 4 (1987) 455-458
40. Evans D.A., Mahgoub A., Sloan T.P., Idle J.R., and Smith R.L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17 2 (1980) 102-105
41. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97 1 (2005) 30-39
42. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 36 (2005) 9312-9318
43. Schroth W., Antoniadou L., Fritz P., et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25 33 (2007) 5187-5193
44. Bijl MJ, van Schaik RH, Lammers LA, et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009 Feb 3 [Epub ahead of print].
45. Goetz M.P., Knox S.K., Suman V.J., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101 1 (2007) 113-121
46. Nowell S.A., Ahn J., Rae J.M., et al. Association of genetic variation in tamoxifenmetabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91 3 (2005) 249-258
47. Wegman P., Elingarami S., Carstensen J., Stal O., Nordenskjold B., and Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9 1 (2007) R7
48. Wegman P., Vainikka L., Stal O., et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7 3 (2005) R284-R290
49. Thuerlimann B., Koeberle D., and Senn H.J. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations. Eur J Cancer 43 1 (2007) 46-52